NASDAQ: BLPHBellerophon Therapeutics Inc Stock
$6.47-0.31 (-4.57%)
Updated Mar 17, 2023
BLPH Price
$6.47
Fair Value Price
$9.07
Market Cap
$61.76M
52 Week Low
$0.67
52 Week High
$7.88
P/E
-3.24x
P/B
8.31x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$19.09M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.7
Operating Cash Flow
-$17M
Beta
-0.27
Next Earnings
Mar 29, 2023
Ex-Dividend
N/A
Next Dividend
N/A
BLPH Overview
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BLPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLPH ($6.47) is undervalued by 28.69% relative to our estimate of its Fair Value price of $9.07 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BLPH ($6.47) is significantly undervalued by 28.69% relative to our estimate of its Fair Value price of $9.07 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BLPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BLPH due diligence checks available for Premium users.
Be the first to know about important BLPH news, forecast changes, insider trades & much more!
BLPH News
Valuation
BLPH fair value
Fair Value of BLPH stock based on Discounted Cash Flow (DCF)
Price
$6.47
Fair Value
$9.07
Undervalued by
28.69%
BLPH ($6.47) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BLPH ($6.47) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BLPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BLPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.24x
Industry
16.18x
Market
21.81x
BLPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.31x
Industry
4.75x
BLPH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BLPH's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.1M
Profit Margin
0%
BLPH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.6M
Liabilities
$5.2M
Debt to equity
0.7
BLPH's short-term assets ($12.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLPH's short-term assets ($12.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLPH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BLPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.0M
Investing
$0.0
Financing
$0.0
BLPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BLPH vs Biotech Stocks
Bellerophon Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.